semaglutide supply shortage news november 2025 (Wegovy) semaglutide supply shortage news november

A synthetic 31-amino acid C18 fatty diacid-conjugated GLP-1 analogue and the most extensively characterised long-acting selective glucagon-like peptide-1 receptor agonist research compound available to laboratories in Ireland and a structurally optimised GLP-1(7-37) analogue incorporating Aib8 substitution for DPP-IV resistance, Arg34Lys substitution eliminating a proteolytic site, and a C18 fatty diacid conjugated via a hydrophilic linker to Lys26 enabling tight reversible albumin binding that produces a circulating half-life of about one week and once-weekly pharmacokinetics activating the GLP-1 receptor through canonical Gs-cAMP-PKA-EPAC2 signal transduction in pancreatic beta cells, hypothalamic appetite-regulating nuclei, brainstem nucleus tractus solitarius, cardiac tissue, and peripheral organs to produce glucose-stimulated insulin secretion potentiation, glucagon suppression, gastric emptying inhibition, pronounced central appetite suppression and body weight reduction, beta cell trophic biology, and cardioprotective signalling

Bird, S

Improved gastric motility: Two studies have linked ipamorelin to improved gastric motility [4, 5]

The cagrilintide research for men and the broader cagrilintide weight loss data point to unique benefits of amylin receptor activation that extend beyond what GLP-1 or GIP agonism provides

Retatrutide Beyond Obesity: The Bigger Clinical Picture Most patients searching for retatrutide are focused on weight loss